**Biography**

**Meet Our Guest of Honor and Recipient of the 2016 Global Leadership Award**

**Hervé Hoppenot
President and Chief Executive Officer
Incyte Corporation**

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8,000 employees in 50 countries. Mr. Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing.

He started his career in 1983 with Rhone Poulenc, which later merged and went on to form Sanofi-Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit.

Mr. Hoppenot holds a diploma from ESSEC Business School, near Paris.  His wife Anne Hoppenot is the Honorary Consul of France in Princeton, NJ.

**About Incyte Corporation**

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.

World-class science and R&D drives Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases. The Company’s first commercial product, Jakafi, is the first and only approved treatment for, myelofibrosis[[1]](#endnote-1) and polycythemia vera[[2]](#endnote-2). two rare blood cancers knows as myeloproliferative neoplasms.

Incyte also has a diverse and growing clinical portfolio that continues to show great progress— the Company currently has 13 development molecules against 10 different targets and through its developed products and clinical collaborations has more than 80 ongoing clinical studies, both proof-of-concept and pivotal trials.

Headquartered in Wilmington, Delaware with European operations in Geneva, Switzerland, Incyte currently employs more than 700 people. For more information, visit [www.incyte.com](http://www.incyte.com).

1. MF is a rare blood cancer in which scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. MF is a serious, chronic and progressive condition. [↑](#endnote-ref-1)
2. PV is a rare, chronic blood disease in which a person’s body makes too many red blood cells, and may also result in too many white blood cells or platelets. Too many red blood cells can cause the blood to thicken, leading to blood clots that block the flow of blood through the arteries and veins. [↑](#endnote-ref-2)